Viewing stories from February, 2023

28 February 2023
Interim Report and Half-Year Financial Results - H1FY23 (ASX Announcement)

Melbourne, Australia; 28 February 2023: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today releases its interim report and half-year financial results for the period ended 31 December 2022 (H1 FY23).

Read More

1 February 2023
Appointment of Company Secretary (ASX Announcement)

Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) advises, in accordance with ASX Listing Rule 3.16.1, that Ms Tracy Weimar from Vistra Australia has been appointed as interim Company Secretary, effective today.

Read More

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.